Asif Iqbal Khan

Dr. Asif Iqbal Khan

Dalian Medical University, Dalian, Liaoning, China
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2022 in Molecules
Verified
Journal Article
Open access
PDF file
AKAsif Iqbal Khan
Asif Iqbal Khan
ARATA UR REHMAN
ATA UR REHMAN
NFNabeel Farooqui
Nabeel Farooqui
Nimra Zafar SiddiquiNimra Zafar Siddiqui
Nimra Zafar Siddiqui
QAQamar Ayub
Qamar Ayub
YXYi Xin
Yi Xin
The gut microbiota is important in regulating host metabolism, maintaining physiology, and protecting immune homeostasis. Gut microbiota dysbiosis affects the development of the gut microenvironment, as well as the onset of various external systemic diseases and metabolic syndromes. Cyclophosphamide (CTX) is a commonly used chemotherapeutic drug that suppresses the host immune system, intestinal mucosa inflammation, and dysbiosis of the intestinal flora. Immunomodulators are necessary to enhance the immune system and prevent homeostasis disbalance and cytotoxicity caused by CTX. In this study, shrimp peptide hydrolysate (SPH) was evaluated for immunomodulation, intestinal integration, and microbiota in CTX-induced immunosuppressed mice. It was observed that SPH would significantly restore goblet cells and intestinal mucosa integrity, modulate the immune system, and increase relative expression of mRNA and tight-junction associated proteins (Occludin, Zo-1, Claudin-1, and Mucin-2). It also improved gut flora and restored the intestinal microbiota ecological balance by removing harmful microbes of various taxonomic groups. This would also increase the immune organs index, serum levels of cytokines (IFN-ϒ, IL1β, TNF-α, IL-6), and immunoglobin levels (IgA, IgM). The Firmicutes/Bacteroidetes proportion was decreased in CTX-induced mice. Finally, SPH would be recommended as a functional food source with a modulatory effect not only on intestinal microbiota, but also as a potential health-promoting immune function regulator.

17 September 2022 in Gut Pathogens
Verified
Journal Article
Open access
PDF file
Nimra Zafar SiddiquiNimra Zafar Siddiqui
Nimra Zafar Siddiqui
ARAta Ur Rehman
Ata Ur Rehman
WYWaleed Yousuf
Waleed Yousuf
AKAsif Iqbal Khan
Asif Iqbal Khan
NFNabeel Farooqui
Nabeel Farooqui
LWLiang Wang
Liang Wang
Type-1 Diabetes Mellitus (T1DM) is regarded as a multifunctional, immune-related disease which causes massive destruction of islet β-cells in pancreas resulting in hyperglycemic, hypoinsulinemia and hyperlipidimic conditions. The aim of the present study, was to investigate the hypothesis that streptozotocin (STZ)-induced T1DM in Balb/c mice when treated with crude polysaccharide from seaweed, Dictyopteris divaricata (CDDP) depicts improvement in diabetes-related symptoms. Treatment with CDDP resulted in decreased body weight loss, improved food consumption and water intake disbalances. The CDDP effectively improved fasting blood glucose, oral glucose tolerance (OGTT), serum insulin, insulin secretion, rejuvenation of β-cells mass, serum lipid profile and pro-inflammatory cytokines levels. Additionally, treatment with CDDP increased the population of beneficial bacteria such as Firmicutes, Bacteroidetes and Lactobacillus at phylum, family and genus levels by 16S rRNA sequencing. Furthermore, immunohistological examination confirmed that CDDP reduces the inflammation and restored the structural morphology of colon and upraised the levels of insulin receptor substrate-1 (IRS-1), Mucin-2 (MUC-2) and tight-junction proteins (TJs) whereby maintaining the gut structures and barrier permeability. Thus, the above presented data, highlights the safe and therapeutic effects of crude polysaccharide (CDDP) from D. divaricata in the treatment and restoration of T1DM disorders and can be used as a food supplement alternative to diabetes medicine.

28 May 2022 in Journal of Food Biochemistry
Verified
Journal Article
Closed access
AKAsif Iqbal Khan
Asif Iqbal Khan
ARAta Ur Rehman
Ata Ur Rehman
NFNabeel Ahmed Farooqui
Nabeel Ahmed Farooqui
NSNimra Zafar Siddiqui
Nimra Zafar Siddiqui
QAQamar Ayub
Qamar Ayub
LWLiang Wang
Liang Wang

11 November 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
DADuaa M. Alsholi
Duaa M. Alsholi
GYGhazi Suleiman Yacoub
Ghazi Suleiman Yacoub
ARATA UR REHMAN
ATA UR REHMAN
HUHIDAYAT ULLAH
HIDAYAT ULLAH
AKAsif Iqbal Khan
Asif Iqbal Khan
YXYi Xin
Yi Xin
Lactobacillus rhamnosus (LBS) is a well-documented probiotic strain in oncology and has a pivotal role in clinical applications. Here, we have investigated the protective effect of Lactobacillus rhamnosus on intestinal mucositis induced by cisplatin (CP) and explored the underlying mechanisms targeting inflammatory proteins, as well as the histological changes in the intestinal tissue of mice, in addition, the bacterial strains that may be related to the health-enhancing properties. BALB/c mice were pre-treated with or without LBS via oral gavage, followed by mucositis induction with cisplatin. Our results revealed that the LBS-treated groups significantly attenuated proinflammatory cytokine levels (IL-1β, IL-6, and TNF-α) compared to the CP group. Furthermore, LBS mitigated the damaged tight junction integrity caused by CP via up-regulating the levels of claudin, occludin, ZO-1, and mucin-2 protein (MUC-2). Finally, the 16S rRNA fecal microbiome genomic analysis showed that LBS administration enhanced the growth of beneficial bacteria, i.e., Firmicutes and Lachnospiraceae, while the relative abundance of the opportunistic bacteria Bacteroides and Proteobacteria decreased. Collectively, LBS was found to beneficially modulate microbial composition structure and functions and enrich the ecological diversity in the gut.

22 January 2025 in AMB Express
Verified
Journal Article
Open access
PDF file
XZXiaoxiao Zhang
Xiaoxiao Zhang
LWLiang Wang
Liang Wang
AKAsif Iqbal Khan
Asif Iqbal Khan
ARAta Ur Rehman
Ata Ur Rehman
KKKavish Hasnain Khinsar
Kavish Hasnain Khinsar
YXYi Xin
Yi Xin
Chemotherapeutic therapies for cancer are frequently associated with cytotoxic side effects that can be harmful to human health, including the development of intestinal mucositis (IM). It mostly affects the gastrointestinal tract, causing ulceration, inflammation, and the formation of lesions in the colon. Surprisingly, despite the frequency of IM, therapeutic choices remain restricted. In our search for new intestinal mucositis therapies, we wanted to see how Lentinan (LT), derived from Lentinus edodes, would fare in mouse models of intestinal mucositis. To create the intestinal mucositis model in mice, we gave them intra-peritoneal doses of 5-fluorouracil (5-FU) (50 mg/kg) and then tested the effects of Lentinan on intestinal mucositis. This examination required constant monitoring of several factors, such as body weight fluctuations, food consumption, and diarrhea. In addition, we measured the levels of certain inflammatory cytokines (Tumour Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), Interleukin-6 (IL-6), and Interleukin-10 (IL-10), looked at the expression of tight junction proteins (Zonula Occludens-1(ZO-1), Claudin-1), measured mucin-2 levels, and looked into changes in the gut flora. In the mouse model of intestinal mucositis, our findings showed that LT effectively reduced weight loss, increased food intake, and relieved diarrhea. Concurrently, we saw a decrease in the expression of inflammatory cytokines such as TNF-α, IL-1, and IL-6, as well as a considerable increase in the concentration of IL-10. Furthermore, LT reduced intestinal mucositis by increasing the length and structural integrity of the colon. Furthermore, increased expression of tight junction proteins (ZO-1, Claudin-1), mucin-2, and an increase in the number of goblet cells all confirmed our previous findings. Notably, the makeup of beneficial bacteria in the stomach increased as well. Finally, our findings suggest that LT can effectively prevent 5-fluorouracil-induced intestinal mucositis in mice by improving immune function, restoring intestinal barrier integrity, and rebalancing gut microbial flora.

30 June 2023 in Microbiological & Immunological Communications
Verified
Journal Article
Open access
PDF file
AKAsif Iqbal Khan
Asif Iqbal Khan
YXYi Xin
Yi Xin
The gut bacteria and the host have a mutually beneficial relationship. This complex interdependence plays a critical role in resource collection via prebiotic carbohydrate breakdown in the intestinal tract, the supply of important nutrients, vitamin synthesis, metabolic operations and maintenance, as well as sheltering against colonization of pathogens, and opportunistic fungal infections. This leads to ‘gut microbiota homeostasis’ or ‘gut microbial equilibrium’, i.e., a stable and healthy gastrointestinal tract microbial community. In this review, we discuss the gut micro biome’s role in the development of the immune system, including oral tolerance and immunity. The therapeutic approach must begin with the interaction of functional foods and enterocytes. Furthermore, we discuss current knowledge and the promising application of functional foods that may stimulate the immune system to perform a further pro- or anti-inflammatory activity in the gastrointestinal system. When evaluating the immune system function of nutraceuticals, designs that modulate the membrane must be used whenever possible. Moreover, nutraceutical products’ claim to be immunity boosters should have valid and accurate data to back it up. While assessing the stimulation of blood cell immunity through functional foods is more useful, it does not accurately reflect physical reality, and an investigation into the colonic immune response is a better way to understand it.